RecruitingPhase 3NCT06692712
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
Studying Hereditary spastic paraplegia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Elpida Therapeutics SPC
- Intervention
- MELPIDA(genetic)
- Enrollment
- 24 enrolled
- Eligibility
- All sexes
- Timeline
- 2026 – 2032
Study locations (2)
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- Sant Joan de Deu, Barcelona, Spain
Collaborators
University of Texas Southwestern Medical Center · Hospital Sant Joan de Deu
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06692712 on ClinicalTrials.gov